U.S. Markets open in 64 hrs, 5 mins
| Symbol | Value | Change | Percentage Change |
|---|---|---|---|
| DJIA | 8,451.19 | -128.00 | -1.49% |
| NASDAQ | 1,649.51 | 4.39 | 0.27% |
| S&P 500 | 899.22 | -10.70 | -1.18% |
| Day Low 02:07 PM EDT | 1.77 | |
|---|---|---|
| Day High 11:41 AM EDT | 2.2618 |
|
| Range | 0.49 | |
| Volume | 15,110 | |
| 30-Day Avg. Vol. | 35,000 |
|
| Difference | -56.83% | |
| Market Cap. | 37.14 M | |
| Change | -5.17 M | |
| Shares Out. | 17.85 M | |
| Percent Traded | 0.08% | |
| Revenue (LFY) | 20.14 M | |
| Earnings (TTM) | -23.31 M | |
| Next Earnings | 11/10/2008 |
|
| EPS (TTM) | -1.32 |
| 52-Wk Low 2:07 PM EDT | 1.77 | |
|---|---|---|
| 52-Wk High 10/31/07 | 13.50 |
|
| Range | 11.73 | |
| Prev. Close 10/9/08 | 2.37 | |
| Today's Open | 2.22 | |
| Change | -6.33% | |
| Dividend (TTM) | 0.00 | |
| Div. Yield (TTM) | 0.00% |
|
| Beta | — | |
| P/E Ratio (TTM) | — | |
| P/E Ratio (Fwd.) | -1.00 |
Trubion Pharmaceuticals' aim is TRU. The company is developing TRU-015, a clinical-stage drug for the treatment of autoimmune diseases including rheumatoid arthritis (currently in late-stage clinical trials) ... View Full Description
| Earnings/Share(EPS) | Estimate | Actual | Difference |
|---|---|---|---|
| 2 Quarters Ago | -0.39 3/31/08 | -0.33 3/31/08 |
0.06
Beat
|
| Last Quarter | -0.47 6/30/08 | -0.37 6/30/08 |
0.10
Beat
|
| Quarterly - 06/30/2008 | Annual - 2007 | |
|---|---|---|
| Total Revenue | 4.47 M | 20.15 M |
| Gross Profit | -2.57 M | -16.32 M |
| Operating Income | -6.95 M | -27.15 M |
| Net Income | -6.63 M | -23.31 M |
